Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology - PubMed (original) (raw)

Practice Guideline

. 2020 Apr;18(4):452-478.

doi: 10.6004/jnccn.2020.0016.

Benjamin O Anderson 2, Jame Abraham 3, Rebecca Aft 4, Doreen Agnese 5, Kimberly H Allison 6, Sarah L Blair 7, Harold J Burstein 8, Chau Dang 9, Anthony D Elias 10, Sharon H Giordano 11, Matthew P Goetz 12, Lori J Goldstein 13, Steven J Isakoff 14, Jairam Krishnamurthy 15, Janice Lyons 3, P Kelly Marcom 16, Jennifer Matro 17, Ingrid A Mayer 18, Meena S Moran 19, Joanne Mortimer 20, Ruth M O'Regan 21, Sameer A Patel 13, Lori J Pierce 22, Hope S Rugo 23, Amy Sitapati 7, Karen Lisa Smith 24, Mary Lou Smith 25, Hatem Soliman 26, Erica M Stringer-Reasor 27, Melinda L Telli 6, John H Ward 28, Jessica S Young 29, Jennifer L Burns 30, Rashmi Kumar 30

Affiliations

Practice Guideline

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

William J Gradishar et al. J Natl Compr Canc Netw. 2020 Apr.

Abstract

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources